2016-03-15T00:00:00.000-04:00
business’s revenue,-0.456351
AnalystRatings.NET reports,-0.402487
hepatic infectious disease,-0.762958
quarter worth,0.27609
quarterly earnings results,-0.265371
Asset Management Inc.,0.504104
Reynolds Capital Management,0.29586
chief executive officer,0.228827
hold rating,-0.248011
InvestorPlace Broker Center,0.555736
trading volume,-0.451196
average price target,-0.333432
biopharmaceutical company,0.422091
SEC website,0.55109
Fortaleza Asset Management,0.504104
personal trading style,0.598412
buy rating,-0.248011
CIBC Asset Management,0.413591
average price,-0.333432
Alnylam Pharmaceuticals Inc.,0.560435
shares,-0.0128925
concise daily summary,0.448938
Alnylam Pharmaceuticals,0.359153
Sei Investments Co.,0.375988
stock broker,0.245696
mid-day trading,-0.323116
consensus rating,0.427449
hepatic infectious diseases,-0.777447
RNAi therapeutics,-0.56796
rating,0.179438
previous session,-0.546435
quarter,-0.0871785
new stake,0.27609
